Shortage of remifentanil injection (all strengths)

· London and South East Regional Medicines Information

The shortage has partly arisen due to issues last year when GSK suspended manufacturing of the drug at its plant in Parma and partly due to shortages of active pharmaceutical ingredient. Also Pfizer/Hospira have discontinued their product and Teva is out of stock. Currently those companies holding stock or who are expecting further supplies will not have sufficient to cover current usage. This memo discusses management of existing stock and alternative treatment options should stock run out.

 

Anaesthesia and painNewsRemifentanilShortages and discontinuations

Attachments